Overweight as an adverse prognostic factor for non-Hodgkin's lymphoma patients receiving high-dose chemotherapy and autograft

C. Tarella, D. Caracciolo, P. Gavarotti, C. Argentino, F. Zallio, P. Corradini, D. Novero, C. Magnani, A. Pileri

Research output: Contribution to journalArticlepeer-review

Abstract

Despite detailed evaluation of disease-associated prognostic factors, little is known about the impact of overweight in autograft programs for non-Hodgkin's lymphoma (NHL) patients. In order to address this issue, 121 NHL patients were retrospectively evaluated. They had been upfront (92 patients) or in relapse (29 patients) and received high-dose sequential (HDS) chemotherapy including peripheral blood progenitor cell (PBPC) autograft. Body mass index (BMI) was calculated as weight in kilograms divided by the square of the height in meters; overweight was defined as BMI ≥28. Univariate and multivariate analyses were used to determine the prognostic implication of overweight and other known prognostic indicators on overall (OS) and event-free (EFS) survival for the entire group and overweight and non-overweight (reference) subgroups. With a median follow-up of 3 years, the estimated 5-year OS and EFS for the entire group were 58% and 49%, respectively. Twenty-eight patients (23%) had BMI ≥28. Their median OS and EFS were 2.2 and 1.4 years, respectively, whereas median OS and EFS for the reference group have not been reached, with a 5-year projection of 65 and 55%, respectively (P

Original languageEnglish
Pages (from-to)1185-1191
Number of pages7
JournalBone Marrow Transplantation
Volume26
Issue number11
Publication statusPublished - 2000

Keywords

  • Autograft
  • High-dose chemotherapy
  • Non-Hodgkin's lymophoma
  • Overweight
  • Prognosis

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Overweight as an adverse prognostic factor for non-Hodgkin's lymphoma patients receiving high-dose chemotherapy and autograft'. Together they form a unique fingerprint.

Cite this